Home Tags SGN35-027

Tag: SGN35-027

Brentuximab vedotin + Immunotherapy Shows 98% ORR and 93% CR in...

Updated efficacy and safety results from Part C of a phase 2 single-arm trial (SGN35-027; ClinicalTrials.gov identifier: NCT03646123; EudraCT 2020-004027-17) evaluating brentuximab vedotin (Adcetris®; Seagen/Takeda)* in combination with the PD-1 inhibitor nivolumab (Opdivo®; Bristol-Myers Squibb) and standard chemotherapy agents doxorubicin (Adriamycin®) and dacarbazine (DTIC-Dome®/Imidazole) for the frontline treatment of patients with early-stage classical Hodgkin lymphoma (cHL).